Results 71 to 80 of about 87,574 (284)

Long-term efficacy and safety of Hizentra® in patients with primary immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials [PDF]

, 2018
Many patients with primary immunodeficiency (PID) require immunoglobulin G (IgG) replacement therapy, delivered as intravenous IgG (IVIG) or subcutaneous IgG (SCIG). We aim to identify trends in efficacy and safety that would not be evident in individual
Borte, Michael, Imai, Kohsuke, Jolles, Stephen, Kanegane, Hirokazu, Lawo, John-Philip, Nelson, Robert, Rojavin, Mikhail A., Tortorici, Michael A., Wasserman, Richard L.   +8 more
core   +2 more sources

Advances in Bioprinting to Model Immune‐Mediated Skin Diseases

Advanced Healthcare Materials, EarlyView.
This review explores how 3D bioprinting drives innovation in developing in vitro skin models that mimic immune‐mediated diseases. It highlights current technologies, key applications in studying skin pathologies, and emerging challenges. The review points toward future opportunities for improving disease modeling and advancing therapeutic and cosmetic ...
Andrea Ulloa‐Fernández, Marica Markovic, Julia Fernández‐Pérez, Georg Stary, Aleksandr Ovsianikov   +4 more
wiley   +1 more source

Outcome evaluation of a subcutaneous immunoglobulin clinical management program

Journal of Research in Pharmacy Practice, 2019
Objective: The aim of this study is to compare clinical and cost outcomes of patients undergoing subcutaneous immunoglobulin (SCIG) therapy who were managed by a clinical management program to the matched controls in the United States.
Julia Zhu, Gretchen Ayer, Heather S Kirkham, Chi-Chang Chen, Rolin L Wade, Swapna U Karkare, Chester H Robson, Jordan S Orange   +7 more
doaj   +1 more source

What is the burden of immunoglobulin replacement therapy in adult patients with primary immunodeficiencies? A systematic review [PDF]

, 2018
© 2018 Jones, Vogt, Chambers, Clowes and Shrimpton. Background: Primary immunodeficiency disorders (PIDs) are a group of heterogeneous rare disorders, whereby the immune system is missing or not functioning adequately.
Ballow, Beaute, Berger, Bienvenu, Borte, Chapel, Chapel, Daly, Dash, Espanol, Eton, Gardulf, Gardulf, Gardulf, Gardulf, Gardulf, Gardulf, Gardulf, Hansen, Heath, Howard, Jiang, Jones, Kittner, Misbah, Mohamed, Mozaffari, Nicolay, Picard, PID, Quinti, Quinti, Rider, Routes, Sav, Skoda-Smith, Sorensen, Tabolli, Tcheurekdjian, Vultaggio, Wood   +40 more
core   +4 more sources

Low‐Temperature Fabrication of Thymosin β4‐Loaded Soluble Microneedles to Promote Wound Healing by Specific Binding to Downregulated Immune Regulators Vsig4 and IL22rɑ2

Advanced Healthcare Materials, EarlyView.
Schematic diagram depicting the fabrication and application of thymosin β4 (Tβ4)‐loaded microneedle patches for wound treatment. The Tβ4 was loaded into chitosan (CS) and sucrose MNs under mild conditions (4°C, 65% relative humidity). The Tβ4 MN patch specifically binds to the downregulated immune regulators Vsig4 and IL22rα2, thereby accelerating ...
Shilong He, Mei Yuan, Changkang Feng, Yixuan Zhang, Jinjing Che   +4 more
wiley   +1 more source

Immunoglobulin replacement therapies in inborn errors of immunity: a review

Frontiers in Pediatrics
Immunoglobulins (Ig) were used as a therapeutic modality for the first time in a patient with X-linked agammaglobulinemia in 1952 by Colonel Ogden Bruton, decades before the molecular mechanisms causing the disease were unraveled.
Archan Sil, Suprit Basu, Vibhu Joshi, Rakesh Kumar Pilania, Sangeetha Siniah, Deepti Suri, Amit Rawat, Surjit Singh   +7 more
doaj   +1 more source

IgM Augments Complement Bactericidal Activity with Serum from a Patient with a Novel CD79a Mutation [PDF]

, 2018
Antibody replacement therapy for patients with antibody deficiencies contains only IgG. As a result, concurrent IgM and IgA deficiency present in a large proportion of antibody deficient patients persists.
Burg, M. (Mirjam) van der, Flier, M. (Michiel) van der, Henriet, S.S.V. (Stefanie S.V.), Jonge, M.I. (Marien) de, Kuipers, S. (Saskia), Langereis, J.D. (Jeroen), Weemaes, C.M.R. (Corry)   +6 more
core   +1 more source

Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?

Current Pharmaceutical Design, 2016
Cumulative recent evidence from clinical trials, observational studies and case reports has shown that subcutaneous administration of immunoglobulin (SCIg) exerts similar immunomodulatory capacity than intravenous immunoglobulin (IVIg) in autoimmune neurological diseases.
Sánchez-Ramón, Silvia, Corbí, Angel L., Fidalgo, Á. G., Domínguez-Soto, Ángeles   +3 more
openaire   +3 more sources

Ferritin‐Doped Nanoparticles Triggered Tumor‐Specific Darkening for Enhanced Photothermal Tumor Ablation and Immune Activation

Advanced Healthcare Materials, EarlyView.
Ferritin‐doped hybrid nanoparticles triggered accurate tumor‐specific hemorrhage for enhanced in situ photothermal therapy and evoked anti‐tumor immunity. Notably, HFn/GA‐Fe specifically induced tumor hemorrhage 12 h after intravenous injection, resulting in visible color darkening. Through photoacoustic imaging, tumor vessels could be clearly observed
Haidong Zha, Xiao Liang, Long Xi, Jiamao Chen, Wenzhao Zhong, Zhen Yuan, Meng Xu, Ying Zheng   +7 more
wiley   +1 more source

Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies

Frontiers in Immunology, 2020
Facilitated subcutaneous immunoglobulin (fSCIG) replacement therapy is the latest method of IgG administration; however, real-life data are limited. We retrospectively analyzed the everyday experience of fSCIG administration, particularly, the method ...
Ewa Wiesik-Szewczyk, Dariusz Sołdacki, Dariusz Sołdacki, Leszek Paczek, Karina Jahnz-Różyk   +4 more
doaj   +1 more source